Skip to Main Content

Paper Details

Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.
Contemp Clin Trials
2
2022
APOL1, APOL1 genotype, APOL1 risk, APOL1 risk alleles, CKD, cardiovascular disease, chronic kidney disease, hypertension, participants, patient, patients, pharmacogenomic genotype, risk alleles
Author NameAffiliation
Michael T EadonIndiana University School of Medicine
Lori A OrlandoDuke University School of Medicine
Peter MerrillDuke Clinical Research Institute
Emily J CicaliUniversity of Florida
Victoria M PrattIndiana University School of Medicine
Marc B RosenmanNorthwestern University Feinberg School of Medicine
Girish N NadkarniIcahn School of Medicine at Mount Sinai
Girish N NadkarniIcahn School of Medicine at Mount Sinai
Ebony B MaddenNational Human Genome Research Institute
Simona VolpiNational Human Genome Research Institute
Simona VolpiNational Human Genome Research Institute
Julie A JohnsonUniversity of Florida
Rhonda M Cooper-DeHoffUniversity of Florida
Carol R HorowitzInstitute for Health Equity Research, Icahn School of Medicine at Mount Sinai
  • 1 - 14

Datasets

Release 1.2